Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

24.18 -0.11 (-0.47%)
Streaming Delayed Price Updated: 12:56 PM EDT, Jun 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
3 No-Brainer Dividend Stocks to Buy Right Now ↗
AbbVie, J&J, and Pfizer are all reliable income plays in this choppy market. 
Via The Motley Fool
Topics Intellectual Property
News headline image
3 Monster Stocks to Buy Right Now With Dividend Yields of 5% or More ↗
Why settle for puny yields when you can buy these monster dividend stocks? 
Via The Motley Fool
Topics ETFs Energy
News headline image
A CFO Departure. A Clinical Miss. A $43 Billion Question Mark. Should You Throw in the Towel on Pfizer Stock? ↗
Things are going from bad to worse for the pharmaceutical giant. 
Via The Motley Fool
Topics Intellectual Property
Most active S&P500 stocks in Wednesday's session ↗
Via Chartmill
News headline image
Opinion: Pfizer Is a Fantastic Dividend Stock for Income Investors to Buy Right Now ↗
Pfizer is deeply out of favor on Wall Street, which could be a huge opportunity for long-term dividend investors. 
Via The Motley Fool
Topics Intellectual Property
News headline image
The Market Just Pulled Back Again. These 3 Blue Chips Are the Ones to Buy. ↗
Take advantage of short-term weakness by stepping into the right long-term investments when they go on sale. 
Via The Motley Fool
Topics Artificial Intelligence Credit Cards Earnings
News headline image
Here's How Many Shares of Pfizer You Must Own to Get $5,000 in Yearly Dividends ↗
The sizable yield comes with a concerning footnote. Just look at the rest of the story. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Alphabet Is Joining the Dow Jones Industrial Average. 3 Surprising Reasons Why SpaceX Could Be Next. ↗
With just 30 components, the Dow's exclusivity is built on industry leadership, which SpaceX has in spades. 
Via The Motley Fool
Topics Artificial Intelligence Stocks
News headline image
AbbVie vs. Pfizer: Which Pharma Giant Stock Is a Better Buy in 2026? ↗
AbbVie and Pfizer are taking divergent paths to navigate patent expirations and competition. Dig into their financials, risk profiles, and valuation metrics. 
Via The Motley Fool
Topics Intellectual Property
News headline image
An Analyst Just Declared Eli Lilly the "Clear Winner" of an American Diabetes Association Conference Focused on Weight-Loss Drugs. Novo's Chief Scientist Disagrees. Who's Right? ↗
Novo Nordisk is no longer the front-runner, but it's not out of the running, either. 
Via The Motley Fool
News headline image
FDA Expands Pfizer's Ibrance Label For Frontline Maintenance In Advanced Breast Cancer ↗
The FDA approves Pfizer's Ibrance regimen for HR+, HER2+ metastatic breast cancer maintenance after positive Phase 3 data. 
Via Benzinga
News headline image
2 Large-Cap Stocks to Target This Week and 1 We Find Risky
Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit... 
Via StockStory
News headline image
Pfizer Declares Third-Quarter 2026 Dividend
From Pfizer Inc.
Via Business Wire
News headline image
The Highest Dividend Yields Are Often the Least Safe. Here's How to Tell the Difference. ↗
Income investors are drawn to the biggest yields, but the biggest yields frequently belong to the companies the market trusts least. A yield is simply the 
Via Talk Markets
News headline image
FDA Approves Pfizer’s IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance
From Pfizer Inc.
Via Business Wire
Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
Via Investor Brand Network
BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Targets Next Generation of DNA Damage Response Cancer Therapies
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Pfizer Stock Trades Flat Following Mixed Phase 3 Lung Cancer Trial Data ↗
Pfizer shares are trading flat in Wednesday's premarket as traders weigh mixed Phase 3 trial headlines alongside a firmer overnight tape. 
Via Benzinga
News headline image
Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
From BioMedWire
Via GlobeNewswire
News headline image
2 High-Yield Dividend Stocks to Buy and Hold for a Decade ↗
Don't wait until they recover to initiate positions. 
Via The Motley Fool
Topics Artificial Intelligence Economy Initial Public Offering
Explore the S&P500 index on Tuesday and find out which stocks are the most active in today's session. ↗
Via Chartmill
News headline image
Pfizer's Lung Cancer Drug Candidate Falls Short Overall, Shows Benefit In Select Patients ↗
Pfizer's sigvotatug vedotin missed its Phase 3 OS goal in NSCLC but showed encouraging results in second-line patients. 
Via Benzinga
News headline image
Pfizer Invites Public to View and Listen to Webcast of August 4 Conference Call with Analysts
From Pfizer Inc.
Via Business Wire
News headline image
Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer
From Pfizer Inc.
Via Business Wire
News headline image
Pfizer Stock Edges Lower Monday: What's Going On? ↗
Pfizer shares are trading lower by about half a percent on Monday as investors digest a leadership transition in the finance seat. 
Via Benzinga
News headline image
GEA Group Aktiengesellschaft Targets EUR 7B Revenue, Higher Margins by 2030 ↗
GEA Group Aktiengesellschaft (ETR:G1A) outlined its 2030 growth and profitability targets during an Industrial Technology Conference presentation, with Investor Relations Manager Eduard Biller saying... 
Via MarketBeat
Topics Supply Chain
News headline image
Pfizer Isn't Expecting to Make Any Big Acquisition in the Next Couple of Years, but It's Planning to Do This Instead ↗
The healthcare company is eyeing opportunities related to artificial intelligence, which it believes can enhance its operations. 
Via The Motley Fool
Topics Artificial Intelligence Earnings Intellectual Property
News headline image
GLP-1 Receptor Agonist Market Revenue Analysis Across Key Regions ↗
The global GLP-1 Receptor Agonist Market was valued at USD 66.4 billion in 2025 and is projected to grow from USD 82.0 billion in 2026 to USD 185.3 billion 
Via Talk Markets
News headline image
2 Reasons to Like ZTS and 1 to Stay Skeptical
Zoetis has gotten torched over the last six months - since December 2025, its stock price has dropped 36.6% to $78.46 per share. This was partly driven by it... 
Via StockStory
News headline image
Could Pfizer Stock Be Your Ticket to Generational Wealth? ↗
Pfizer is struggling right now, leaving it in the Wall Street doghouse; it won't be there forever. 
Via The Motley Fool
Topics Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.